Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®

NCT03283319 is registered in ClinicalTrials.gov with Biomedical Advanced Research and Development Authority as lead sponsor.

NCT NCT03283319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®
Lead sponsor
Biomedical Advanced Research and Development Authority
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2017
Completion date
November 9, 2018
Enrollment
366 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human